US2016046991A1PendingUtilityA1
Genetic polymorphisms associated with liver fibrosis, methods of detection and uses thereof
Est. expiryApr 27, 2026(expired)· nominal 20-yr term from priority
C12Q 2600/112C12Q 2600/156C12Q 1/6883C12Q 2600/106C12Q 2600/136C12Q 1/6886C12Q 2600/172C12Q 2600/118
67
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention is based on the discovery of genetic polymorphisms that are associated with liver fibrosis and related pathologies. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, including groups of nucleic acid molecules that may be used as a signature marker set, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.
Claims
exact text as granted — not AI-modified1 . A method for identifying an individual who has an altered risk for developing liver fibrosis, comprising detecting a single nucleotide polymorphism (SNP) in any one of the nucleotide sequences of SEQ ID NOS:1-15 and 31-45 in said individual's nucleic acids, wherein the presence of the SNP is correlated with an altered risk for liver fibrosis in said individual.
2 . The method of claim 1 in which the altered risk is an increased risk.
3 . The method of claim 1 in which the altered risk is a decreased risk.
4 . The method of claim 1 , wherein the SNP is selected from the group consisting of the SNPs set forth in Tables 6 and 7.
5 . The method of claim 1 in which detection is carried out by a process selected from the group consisting of: allele-specific probe hybridization, allele-specific primer extension, allele-specific amplification, sequencing, 5′ nuclease digestion, molecular beacon assay, oligonucleotide ligation assay, size analysis, and single-stranded conformation polymorphism.
6 - 11 . (canceled)
12 . An isolated polynucleotide which specifically hybridizes to a nucleic acid molecule containing a single nucleotide polymorphism (SNP) in any one of the nucleotide sequences in SEQ ID NOS:1-15 and 31-45.
13 . The polynucleotide of claim 12 , which is an allele-specific probe.
14 . The polynucleotide of claim 12 , which is an allele-specific primer.
15 . The polynucleotide of claim 12 , wherein the polynucleotide comprises a nucleotide sequence selected from the group consisting of the primer sequences set forth in Table 5 (SEQ ID NOS:73-93).
16 . A kit for detecting a single nucleotide polymorphism (SNP) in a nucleic acid, comprising the polynucleotide of claim 12 , a buffer, and an enzyme.
17 . (canceled)
18 . A method for identifying an individual who has a risk for progressing rapidly from minimal fibrosis to bridging fibrosis/cirrhosis, comprising detecting a single nucleotide polymorphism (SNP) in any one of the nucleotide sequences of SEQ ID NOS:1-15 and 31-45 in said individual's nucleic acids, wherein the presence of the SNP is correlated with a risk for a rapid rate of progression to bridging fibrosis/cirrhosis in said individual.Join the waitlist — get patent alerts
Track US2016046991A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.